Cat. #161022
NCI/ADR-RES Cell Line
Cat. #: 161022
Organism: Human
Tissue: Ovary
Disease: Cancer
Model: Spectral karyotyping of the 59 cell lines currently in the drug screen panel demonstrates that the Ovarian tumor cell line OVCAR-8 shares a large number of karyotypic abnormalities with the NCI/ADR-RES line
£575.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Kenneth H. Cowan
Institute: National Cancer Institute
Primary Citation: Scudiero et al. 1998. Journal of the National Cancer Institute, Vol. 90, No. 11. PMID: 9625176
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: NCI/ADR-RES Cell Line
- Cancer: Gynaecologic cancer
- Cancers detailed: Ovarian
- Research fields: Cancer
- Organism: Human
- Tissue: Ovary
- Disease: Cancer
- Model: Spectral karyotyping of the 59 cell lines currently in the drug screen panel demonstrates that the Ovarian tumor cell line OVCAR-8 shares a large number of karyotypic abnormalities with the NCI/ADR-RES line
- Crispr: No
- Description: NCI/ADR-RES is a multidrug-resistant cell line that is a model for the study of drug resistance in ovarian cancer
Handling
- Temperature: 37° C
- Atmosphere: 5% CO2
- Shipping conditions: Dry Ice
- Storage conditions: Liquid Nitrogen
